M Reza Maleki-Yazdi

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi request reprint Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
    COPD 4:313-20. 2007
  2. doi request reprint Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstruct
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Appl Health Econ Health Policy 14:579-94. 2016
  3. pmc Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Adv Ther 33:2188-2199. 2017
  4. doi request reprint A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada Electronic address
    Respir Med 109:596-605. 2015
  5. pmc The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada
    M Reza Maleki-Yazdi
    Department of Medicine, Women s College Hospital, University of Toronto, Ontario, Canada
    Can Respir J 19:319-24. 2012

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
    COPD 4:313-20. 2007
    ..Thus, detection of COPD at GOLD stage 0 may provide a unique opportunity for early intervention and smoking cessation and the removal of GOLD stage 0 from the 2006 update should be re-assessed...
  2. doi request reprint Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstruct
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Appl Health Econ Health Policy 14:579-94. 2016
    ....
  3. pmc Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Adv Ther 33:2188-2199. 2017
    ..The aim of this study was to determine whether early initiation of a dual bronchodilator versus monotherapy reduced the risk of deterioration in COPD...
  4. doi request reprint A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease
    M Reza Maleki-Yazdi
    Division of Respiratory Medicine, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada Electronic address
    Respir Med 109:596-605. 2015
    ..Olodaterol is a novel long-acting β2-agonist (LABA) with ≥24-h duration of action in preclinical and clinical studies...
  5. pmc The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada
    M Reza Maleki-Yazdi
    Department of Medicine, Women s College Hospital, University of Toronto, Ontario, Canada
    Can Respir J 19:319-24. 2012
    ..No recent Canadian studies with physician- and spirometry-confirmed diagnosis of chronic obstructive pulmonary disease (COPD) that assessed the burden of COPD have been published...